Mr. Erez Tetro reports

VVT MED ANNOUNCES FIRST PATIENTS TREATED WITH VVT'S SCLEROSAFE SYSTEM IN ITALY

The first group of patients has been treated with VVT Med Inc.'s ScleroSafe system in Italy by Dr. Luca Palombi and his team, in collaboration with the company's local distributor, Uber Ros SpA. The patients were treated at Fondazione Villa Salus Hospital in Mestre, Venice, Italy.

The treatment of first patients marks a milestone in VVT Med's continued European expansion and reflects physician interest in office-based, minimally invasive vein treatment solutions.

"We were pleased to be the first centre in Italy to treat patients with the ScleroSafe system," said Dr. Luca Palombi. "Treating our first patients with the ScleroSafe system demonstrated a distinctly different approach to sclerotherapy: precise, minimally invasive venous procedures while enhancing the overall treatment experience for both physicians and patients."

"We are encouraged by the growing interest in ScleroSafe among leading vein specialists in Europe," said Erez Tetro, chief executive officer of VVT Med. "Italy is an important market for advanced venous care, and we extend our sincere thanks to our valued local distributor, Uber Ros SpA, for their outstanding support in achieving this milestone."

ScleroSafe is designed to enable controlled sclerosant delivery with simultaneous blood aspiration, supporting targeted interaction with the vein wall while eliminating the need for thermal energy or tumescent anesthesia. The technology provides physicians with an efficient, office-based treatment option across a broad range of vein diameters.

About VVT Med Inc.

VVT Medical develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent solutions for the treatment of vein diseases, starting with varicose veins. VVT is the only Food and Drug Administration-cleared, stand-alone company offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.